

NEUROAID™ NEWSLETTER SEPTEMBER 2007

Welcome to the second issue of the Neuroaid™ newsletter. You will find updates on our ongoing clinical trials, new press articles on Neuroaid™ and status of registrations on new markets.



THIS MONTH'S HEADLINES

- 1- [NEUROAID™ REACHING MORE PATIENTS ACROSS THE GLOBE](#)
- 2- [THE RATIONALE BEHIND US\\$12/DAY OVER THREE MONTHS](#)
- 3- [FREE SHIPPING PROMOTION AND ONLINE PAYMENTS](#)
- 4- [UPDATE ON NEW CLINICAL TRIALS](#)
- 5- [MOLEAC AND NEUROAID™ IN THE NEWS](#)
- 6- [WHEN WILL NEUROAID™ BECOME AVAILABLE IN YOUR COUNTRY?](#)

For more information, please visit our websites www.moleac.net and www.neuroaid.com

FULL ARTICLES

1- NEUROAID™ REACHING MORE PATIENTS ACROSS THE GLOBE

Because we believe that every stroke patients has the right to access Neuroaid™ aside his country or continent we are making Neuroaid™ globally available through internet while we pursue the processes of country registration.

After starting in Singapore, Neuroaid™ has reached patients in more than 15 countries. Feedbacks are very positive and we see more and more patients actually ordering a 2nd and 3rd months of treatment after their initial order.

Moreover, a number of patients have decided to start a Neuroaid™ program a year after their stroke event and they are reporting incremental progress on spasticity and motor functions.

We continue to add testimonials to our website and encourage you to submit your personal testimonials.

We are currently enhancing our website and developing the Spanish, French, and German versions. Our multilingual website will allow you to select your preferred language.

You may visit:

www.neuroaid.com/sp www.neuroaid.com/fr www.neuroaid.com/de

2- THE RATIONALE BEHIND US\$12/DAY OVER THREE MONTHS

Neuroaid™ is a unique complex proprietary blend of carefully selected high grade ingredients. The ingredients have been used for many years in traditional medicines and are well known for their properties towards achieving a better recovery. Neuroaid™ has been elaborated by carefully selecting and calibrating these ingredients into a formula that is manufactured with the best quality standards in the late 90's. The clinical trials implemented then, have established Neuroaid™ unique safety and efficacy for recovery.

As opposed to standard dietary supplements offered in most web malls and retails stores, Neuroaid™ has established clinical data, an outstanding quality and sophisticated concoction. These innovations, quality standards and clinical data make Neuroaid™ unique.

Outside Asia, Neuroaid™ is simply a new product. As a result, its costs are not covered yet by health insurers. We are currently undertaking investments in research and development and our aim is to bring the price down as insurers start recognizing benefits of Neuroaid™ to patients, hopefully in less than 3 years.

Neuroaid™ is still a good value for money in regards on its performance and it only needs to be taken for 3 months.

US\$12 per day over 3 months is a good investment.

3- FREE SHIPPING PROMOTION AND ONLINE PAYMENTS

Promotion:

We are running a special promotion campaign until the 15th of September. As a newsletter subscriber, you can benefit from free shipping for the first month of treatment or US\$60 off a 3 months treatment which comes with free shipping.

Online payments:

We have encountered this month some technical problems with our payment partner PAYPAL on online payments; credit card module is now functional, in some rare cases you may be asked to create a paypal account. We are currently working to provide you a seamless experience.

4- UPDATE ON CLINICAL TRIALS

In addition to the existing clinical data showing efficiency several weeks or month after stroke, strong interest from the international medical community is now driving several clinical trials on Neuroaid™.

These trials investigate the effects of Neuroaid™ when taken at very early stage after a stroke (48h) as well as a detailed identification of the effect on rehabilitation components and drivers. Trials are conducted in Asia please contact medical@neuroaid.com for further information.

NAME	START DATE	COUNTRIES INVOLVED	RESEARCH TEAM	DETAILS
CHIMES	October 2007	Singapore, Thailand, Philippines	Prof Donnan (Australia -	1100 stroke survivors recruited within 48h after their stroke. CHIMES has

			Pdt of the World Stroke Organization) Prof MG Bousser (France) Dr Chen (Singapore) See the full team >	recently received the largest grant ever awarded to a single clinical trial in Singapore. More info on the CHIMES website.
TIERS	September 2007	Singapore	Dr Kong KH	TIERS will enroll 40 patients within 1 month of their stroke onset. They will be given Neuroaid™ or placebo for 1 month following which they will be assessed by the Fugl- Meyer, Functional Independence Measure, SCUC and NIHSS score.

5- MOLEAC AND NEUROAID™ IN THE NEWS

Media:

LiveWell: September, October 2007 Issue. As we thought the article “Life goes on after a stroke” may be of interest for you.

The link to the article is: http://www.neuroaid.com/article/livewell_2007_09.pdf

Hope for stroke magazine: August 2007, “The Ruth Lyke Story”. Ruth was actually a patient in the hospital where Neuroaid™ was first discovered.

The link to the article is: <http://www.hope4stroke.com/0907pg2.html>

Conference:

We participated to the Annual Meeting of WFN Neurosonology Research Group (Asian Chapter) and at the regular NNI (National Neuroscience Institute) conference, held on the 31st of August 2007 to 2nd of September 2007 and located at DBS Auditorium, Singapore 068809.

6- WHEN WILL NEUROAID™ BECOME AVAILABLE IN YOUR COUNTRY?

In addition to being available internationally on www.neuroaid.com Neuroaid™ will be available in a number of new countries by the end of the year.

REGION	COUNTRY AND AVAILABILITY DATE
NORTH AMERICA	November 2007 in the USA
EUROPE	2008
ASIA PACIFIC	Available in Singapore, Malaysia

	<i>November 2007 in Thailand</i>
	<i>October 2007 in Philippines</i>
AUSTRALIA/ NEW ZEALAND	2008
MIDDLE EAST	<i>Progressively available as of November 2007 in Lebanon</i>
LATIN AMERICA	2008/2009
AFRICA	<i>Soon in South Africa</i>



Innovative medicines for patients and physicians
Focus on **safety, quality and clinical development**
More information on www.moleac.net

You are receiving our newsletter because you subscribed on the website
www.neuroaid.com

If you want to unsubscribe from this newsletter, please [reply](#) with the word 'REMOVE' in the subject line.